Affordable Access

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

Authors
  • Grey, Andrew
  • Bolland, Mark
  • Gamble, Greg
  • Wattie, Diana
  • Horne, Anne
  • Davidson, James
  • Reid, Ian R
Type
Published Article
Journal
The Journal of clinical endocrinology and metabolism
Publication Date
Apr 01, 2007
Volume
92
Issue
4
Pages
1305–1310
Identifiers
PMID: 17264176
Source
Medline
License
Unknown

Abstract

Short-term therapy with rosiglitazone exerts detrimental skeletal effects by inhibiting bone formation. Skeletal end points should be included in future long-term studies of thiazolidinedione use.

Report this publication

Statistics

Seen <100 times